<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02381652</url>
  </required_header>
  <id_info>
    <org_study_id>Cingal 13-02</org_study_id>
    <nct_id>NCT02381652</nct_id>
  </id_info>
  <brief_title>Repeat Injection of Cingal® for Osteoarthritis of the Knee</brief_title>
  <official_title>An Open-Label, Follow-On Study to Cingal 13-01 to Evaluate the Safety of a Repeat Injection of Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide to Provide Symptomatic Relief of Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anika Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anika Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety of an injection of Cingal® in subjects&#xD;
      with Osteoarthritis (OA) of the knee who participated in Cingal 13-01, and who received&#xD;
      either a Cingal, Monovisc, or saline injection in the 13-01 study. The safety evaluation will&#xD;
      be done by a through examination of the incidence of adverse events and physical examination&#xD;
      of the knee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Cingal 13-02 study is a follow-on study to the recently completed clinical trial Cingal&#xD;
      13-01. Cingal 13-01 was a multi-center, randomized, double-blind, Phase III study that&#xD;
      enrolled 368 subjects at up to 20 sites in Canada and Europe. The Cingal 13-01 study&#xD;
      objective was to assess the safety and effectiveness of a single injection of Cingal® for&#xD;
      relief of joint pain and symptoms in patients with osteoarthritis (OA) of the knee. The study&#xD;
      had three arms: the Cingal® investigational arm, an active comparator arm (Monovisc®) and a&#xD;
      control arm (saline). Cingal 13-02 is designed to evaluate the safety of an open-label&#xD;
      injection of Cingal® in subjects who received a study injection in the Cingal 13-01 trial.&#xD;
      Sites that enrolled 5 or more subjects in the Cingal 13-01 study were eligible to participate&#xD;
      in the Cingal 13-02 study. All subjects at these sites who met enrollment criteria had the&#xD;
      option to participate in the follow-on study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All subjects enrolled into the Cingal 3-02 follow-on study received an intra-articular injection of Cingal. The three 'arms' of the study were for subjects who received a Cingal, Monovisc, or saline initial injection in the Cingal 13-01 study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Cingal 13-02 was an open label follow-up study. The participants, investigators and outcomes assessors were blinded to the specific study injection subjects had previously received in Cingal 13-01.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Comparison of Adverse Event Profile of Cingal 13-02 vs. Cingal 13-01</measure>
    <time_frame>Baseline through 6 weeks post-injection</time_frame>
    <description>The primary outcome measure will compare safety results (all adverse events, whether related to the study injection or not) for Cingal 13-01 and Cingal 13-02.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Cingal/Cingal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who had received an injection of Cingal in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cingal/Monovisc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who had received an injection of Monovisc in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cingal/Saline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who had received an injection of Saline in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Cingal</intervention_name>
    <description>Injection into the knee</description>
    <arm_group_label>Cingal/Cingal</arm_group_label>
    <other_name>Hyaluronic Acid with Triamcinolone Hexacetonide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Cingal</intervention_name>
    <description>Injection into the knee</description>
    <arm_group_label>Cingal/Monovisc</arm_group_label>
    <other_name>Hyaluronic Acid with Triamcinolone Hexacetonide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Cingal</intervention_name>
    <description>Injection into the knee</description>
    <arm_group_label>Cingal/Saline</arm_group_label>
    <other_name>Hyaluronic Acid with Triamcinolone Hexacetonide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject completed Cingal 13-01 and is interested in participating in the follow-on&#xD;
             study&#xD;
&#xD;
          2. Subject must be willing to abstain from other intra-articular or surgical treatments&#xD;
             of the index knee for the duration of the study&#xD;
&#xD;
          3. Subject is willing to discontinue all analgesics except acetaminophen/paracetamol for&#xD;
             the duration of the study&#xD;
&#xD;
          4. Subject is willing to use only acetaminophen/paracetamol (up to a maximum of 4.0 grams&#xD;
             per day per the package insert) for the treatment of joint pain for the duration of&#xD;
             the study. At least twenty-four hours prior to the injection and each follow-up visit,&#xD;
             the subject is willing to discontinue use of acetaminophen/paracetamol&#xD;
&#xD;
          5. Subject is able to understand and comply with the requirements of the study and&#xD;
             voluntarily provides consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject received an intra-articular injection or underwent a surgical procedure of the&#xD;
             index knee since the study injection in Cingal 13-01&#xD;
&#xD;
          2. Subject is taking medication at the time of consent which could interfere with the&#xD;
             treatment procedure, healing and/or assessments. This includes but is not limited to&#xD;
             oral or injectable anticoagulant treatments, anti-aggregant platelet treatment and&#xD;
             opioid analgesics. Low dose aspirin used for cardiovascular protection is allowed if a&#xD;
             stable regimen is maintained for the duration of the study.&#xD;
&#xD;
          3. Subjects who had an oral, intramuscular, intravenous, rectal suppository or topical&#xD;
             (excluded in index knee only) corticosteroid within 30 days of signing the ICF are&#xD;
             excluded. Topical corticosteroid use at any site other than the index knee is allowed.&#xD;
&#xD;
          4. Subject has a contraindication to IA injections, aspiration of the index knee,&#xD;
             corticosteroids, hyaluronan, or acetaminophen/paracetamol.&#xD;
&#xD;
          5. Subject is pregnant or breastfeeding or a woman of child bearing potential who refuses&#xD;
             to use effective contraception during the course of the study.&#xD;
&#xD;
          6. Subject participated in a research study other than Cingal 13-01 within 60 days of&#xD;
             consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laszlo Hangody, MD, PhD, DSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Semmelweis University, Head of Department of Traumatology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piotr Lukasik, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NZOZ Medi-Spatz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Plus s.r.o.</name>
      <address>
        <city>Uherske Hradiste</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Belvaros-Lipotvaros, Orthopedic Outpatient Clinic</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, Department of Orthopaedics</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uzsoki Hospital, Department of Traumatology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jutrix Healthcare Services Ltd.</name>
      <address>
        <city>Kecskemet</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medidea Bt.</name>
      <address>
        <city>Kiskunfelegyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G&amp;V Pharma-Med Bt.</name>
      <address>
        <city>Mako</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Medi-Spatz</name>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ARTIMED Niepubliczny Zaklad Opieki Zdrowotnej w Kielcach</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CenterMed Krakow Sp. z o.o.</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Poland</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 3, 2015</study_first_submitted>
  <study_first_submitted_qc>March 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <results_first_submitted>August 18, 2020</results_first_submitted>
  <results_first_submitted_qc>August 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 3, 2020</results_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Intra-articular Injection</keyword>
  <keyword>Hyaluronic Acid</keyword>
  <keyword>Triamcinolone Hexacetonide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Hyaluronic Acid</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is not a plan to share individual participant data</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited into Cingal 13-02 in February 2015. Sites that enrolled 5 or more subjects in the Cingal 13-01 study were eligible to participate in the Cingal 13-02 study. All subjects at these sites who met enrollment criteria had the option to participate in the follow-on study.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were treated with Cingal in the study. There were no exclusions.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cingal/Cingal</title>
          <description>Subjects who had received an injection of Cingal in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.&#xD;
Cingal: Injection into the knee</description>
        </group>
        <group group_id="P2">
          <title>Cingal/Monovisc</title>
          <description>Subjects who had received an injection of Monovisc in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.&#xD;
Cingal: Injection into the knee</description>
        </group>
        <group group_id="P3">
          <title>Cingal/Saline</title>
          <description>Subjects who had received an injection of Saline in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.&#xD;
Cingal: Injection into the knee</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94">Cingal injection in 13-01 study; receiving a 2nd Cingal injection in 13-02</participants>
                <participants group_id="P2" count="98">Monovisc injection in 13-01 study; receiving a Cingal injection in 13-02</participants>
                <participants group_id="P3" count="50">Saline injection in 13-01 study; receiving a Cingal injection in 13-02</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="98"/>
                <participants group_id="P3" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis population is the Safety Population and consists of all 242 enrolled subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Cingal/Cingal</title>
          <description>Subjects who had received an injection of Cingal in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.&#xD;
Cingal: Injection into the knee</description>
        </group>
        <group group_id="B2">
          <title>Cingal/Monovisc</title>
          <description>Subjects who had received an injection of Monovisc in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.&#xD;
Cingal: Injection into the knee</description>
        </group>
        <group group_id="B3">
          <title>Cingal/Saline</title>
          <description>Subjects who had received an injection of Saline in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.&#xD;
Cingal: Injection into the knee</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
            <count group_id="B2" value="98"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="242"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="8.2"/>
                    <measurement group_id="B2" value="60.2" spread="8.4"/>
                    <measurement group_id="B3" value="60.5" spread="8.8"/>
                    <measurement group_id="B4" value="59.7" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="161"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="242"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety Comparison of Adverse Event Profile of Cingal 13-02 vs. Cingal 13-01</title>
        <description>The primary outcome measure will compare safety results (all adverse events, whether related to the study injection or not) for Cingal 13-01 and Cingal 13-02.</description>
        <time_frame>Baseline through 6 weeks post-injection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cingal 13-01 Adverse Events</title>
            <description>All adverse events that occurred in Cingal 13-01 for 6 weeks post-injection, regardless if considered related to the study injection or not.</description>
          </group>
          <group group_id="O2">
            <title>Cingal 13-02 Adverse Events</title>
            <description>All adverse events that occurred in Cingal 13-02 for 6 weeks post-injection, regardless if considered related to the study injection or not.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Comparison of Adverse Event Profile of Cingal 13-02 vs. Cingal 13-01</title>
          <description>The primary outcome measure will compare safety results (all adverse events, whether related to the study injection or not) for Cingal 13-01 and Cingal 13-02.</description>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="368"/>
                <count group_id="O2" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Statistical test to see if there is a difference</non_inferiority_desc>
            <p_value>0.3108</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected in Cingal 13-02 within the first six weeks after injection.</time_frame>
      <desc>The definitions of adverse events and serious adverse events is the same as used in the clinicaltrials.gov definitions. The incidence, timing, severity, and relationship to treatment of all Adverse Events (AE) were collected and coded using Medical Dictionary for Regulatory Activities (MedDRA).</desc>
      <group_list>
        <group group_id="E1">
          <title>Cingal/Cingal</title>
          <description>Subjects who had received an injection of Cingal in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.&#xD;
Cingal: Injection into the knee</description>
        </group>
        <group group_id="E2">
          <title>Cingal/Monovisc</title>
          <description>Subjects who had received an injection of Monovisc in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.&#xD;
Cingal: Injection into the knee</description>
        </group>
        <group group_id="E3">
          <title>Cingal/Saline</title>
          <description>Subjects who had received an injection of Saline in the 13-01 study will receive a single 4 milliliter (mL) intra-articular injection of Cingal (88 milligrams Hyaluronic Acid plus 18 milligramsTriamcinolone Hexacetonide) in the index knee in the 13-02 study.&#xD;
Cingal: Injection into the knee</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <description>Subject 18-044 received an injection of Cingal® in the left knee, and 18 days later the subject was hospitalized for a meniscus lesion of the right (non-index) knee. The subject had an arthroscopy and the event resolved without sequelae.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <description>Pain at injection site</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>Common cold</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="98"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <description>Generalized joint pain</description>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="98"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <description>Swollen knee</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <description>Limitation of joint movement</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <description>Backache</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="98"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Cingal 13-02 is a follow-on safety trial to Cingal 13-01 and collected safety data only from an open-label injection of Cingal.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Carol Pekar, VP Clinical Affairs</name_or_title>
      <organization>Anika</organization>
      <phone>781.457.9218</phone>
      <email>cpekar@anikatherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

